2.71
0.04 (1.50%)
AIStockmoo Score
| Value 30% | -3.0 |
| Earns below its cost of capital. Returns on capital falling. info | |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -2.5 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend, but its moving averages have flattened. A recent move above resistance has not been confirmed. info | |
| From our AI technical analysis of the chart. info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | 1.8 |
| Institutions net +3.85% of shares in their latest 13F filings: 38 holders increased, 13 decreased (quarter to 30 Sep 2026). info | |
| Short interest +64.0% from 31 Aug to 30 Oct 2026, 8.4 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Recent bullish reversal pattern: Inverted hammer. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | -1.55 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Anixa Biosciences, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ANIX | - | - | - | 6.26 | -1.6 |
| HLVX | 103 M | - | - | 0.710 | 0.0 |
| MEIP | 49 M | - | - | - | 0.0 |
| SONN | 33 M | - | - | 2.07 | -1.4 |
| INAB | - | - | - | 0.570 | -2.5 |
| PLRX | - | - | - | 0.320 | -3.8 |
Select this tab to load the latest available analysis.
|
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.32% |
| % Held by Institutions | 17.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Laird Norton Wetherby Trust Company, Llc | 30 Sep 2026 | 600,727 |
| D.A. Davidson & Co. | 30 Sep 2026 | 494,949 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 22.72%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 38 | 1,216,268 |
| Decreased | 13 | 111,190 |
| New | 16 | 267,256 |
| Sold out | 4 | 26,400 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 1,628,481 | 8.4 |
| 15 Oct 2026 | 1,661,781 | 6.4 |
| 30 Sep 2026 | 1,350,212 | 3.7 |
| 15 Sep 2026 | 1,054,934 | 2.7 |
| 31 Aug 2026 | 993,183 | 3.3 |
| 14 Aug 2026 | 977,973 | 6.3 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development… |
| 04 Nov 2026 | Yahoo Finance |
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of… |
| 26 Oct 2026 | Yahoo Finance |
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129)… |
| 13 Oct 2026 | Yahoo Finance |
Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Learn how Anixa is advancing two clinical-stage oncology programs through differentiated immunotherapy and vaccine approachesManagement to discuss CAR-T clinical progress, completed Phase 1 breast cancer vaccine trial, planned Phase 2 development, and upcoming milestonesORLANDO, FL / ACCESS… |
| 13 Oct 2026 | Yahoo Finance |
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026… |
| 05 Oct 2026 | Yahoo Finance |
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian… |
| 01 Oct 2026 | Yahoo Finance |
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov… |
| 21 Sep 2026 | Yahoo Finance |
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from… |
| 16 Sep 2026 | Yahoo Finance |
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board. |
| 11 Sep 2026 | Yahoo Finance |
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc. |
| 09 Sep 2026 | Yahoo Finance |
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the… |
| 03 Sep 2026 | Yahoo Finance |
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9… |
| 24 Aug 2026 | Yahoo Finance |
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |